



To: Washington University IRB

From: Zachary Prenskey, CEO - LB Pharmaceuticals

Date: December 7, 2020

RE: Clarification Memo #3 - Revised Investigator's Brochure

An Open Label Positron Emission Tomography (PET) Study to Evaluate Dopamine Receptor Occupancy of LB-102 Administered Orally to Healthy Subjects

The intent of this memo is to provide documentation from the sponsor indicating when the revised IB was received by the study team.

Below is documentation indicating when the Study Team received the revised IB. On 24 Nov 2020, Ruthanna Costello from Target Health (CRO) sent the revised IB to Nicole (Nikki) Caito from Washington University at St. Louis.

updated **IB**



Ruthanna Costello <rcostello@targethealth.com>

Tue 11/24/2020 5:19 PM

To: Caito, Nicole



1.14.4.1--investigational-broc... 2 MB	IB _LB-102-002_AoR_Edition 2.... 24 KB
---	--

2 attachments (2 MB) Download all Save all to OneDrive - Washington University in St. Louis

*** External Email - Caution ***

Nikki,

Miguel is not sure he sent this to you, so just in case could you have Dr Wong sign this updated (word document) that is the PI understanding of the updated **IB**.

Ruthanna

Reply | Forward



ZACHARY PRENSKY

Zachary Prenskey, CEO

Zachary Prenskey

Signature

Dec 7th 2020

Date